Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 250 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Severe Side Effects of Cancer Treatment Are More Common in Women... March 15, 2022 Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... June 27, 2023 Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... October 15, 2025 Foodie Friday: Winter Warm-Up White Bean Soup February 11, 2022 Load more HOT NEWS Apple Season is Here! 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib
